We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Decrease in FDA Pandemic-Era Inspections Could Risk Public Health
Decrease in FDA Pandemic-Era Inspections Could Risk Public Health
From March to October 2020, during the height of the COVID-19 pandemic, the FDA conducted just 52 domestic on-site pharmaceutical inspections and all but halted foreign inspections ― moves that have worried some regulatory experts.
